TCMD
Tactile Systems Technology, Inc.28.95
+0.52+1.83%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Reaffirms prior auth preparedness
Q&A largely reaffirmed the prepared script, emphasizing Tactile's readiness for Medicare prior authorization starting April 13 as a short-term industry headwind baked into 8-11% revenue growth guidance, with potential Q3 tweaks. Management unpacked LymphaTech commercialization: current use by garment makers and clinics, future rep integration in high-volume centers after reimbursement progress. Analysts grilled NCD tailwinds versus process delays; execs highlighted AI tools and commercial experience to speed approvals. Q&A added color, not curveballs. EBITDA's record margin drew praise, credited to cost discipline and maturing investments amid sales force annualization. Tone stayed bullish—investors eye prior auth execution.
Key Stats
Market Cap
646.62MP/E (TTM)
38.09Basic EPS (TTM)
0.76Dividend Yield
0%Recent Filings
8-K
Pearson joins TCMD board
Tactile Systems Technology elected Andrea A. Pearson to its board on March 4, 2026, effective March 9, expanding to nine directors. She joins the Compliance & Reimbursement and Nominating & Governance Committees, bringing 25+ years in healthcare growth, including scaling DispatchHealth 30x in revenue. Board adds marketing firepower. Compensation follows standard policy with prorated $155,000 RSUs and $60,000 annual cash retainers.
10-K
FY2025 results
Tactile Systems Technology posted FY2025 revenue of $329.5 million, up 12% y/y from 2024, with net income of $19.1 million; lymphedema products drove 84% ($278.4 million, +7% y/y), while AffloVest airway clearance surged to $51.1 million (+52% y/y). Quarterly breakdowns not disclosed in the 10-K. Q4 saw Nimbl's full-year ramp-up after October 2024 upper-extremity launch, replacing Entre systems. Cash generation trends and debt details unavailable. No annual guidance provided. Medicare coverage changes threaten quarterly reimbursement flows.
8-K
Q4 beat, LymphaTech acquired
Tactile Medical reported Q4 revenue up 21% to $103.6M and full-year 2025 revenue up 12% to $329.5M, with gross margins expanding to 78% and 76%. Acquired LymphaTech for $6.8M upfront cash plus contingent milestones, adding 3D scanning to bolster lymphedema detection and R&D. Guides 2026 revenue to $357M-$365M. Debt-free balance sheet shines.
10-Q
Q3 FY2025 results
Tactile Systems posted Q3 revenue of $85.8M, up 17% y/y from $73.1M, with sales surging 22% while rentals dipped 11%; gross margin ticked up to 76%. Operating income jumped 62% y/y to $11.0M, diluted EPS rose to $0.36 from $0.21 on fewer shares after $26.8M repurchases. Airway clearance products drove 71% y/y growth to 16% of revenue, fueled by DME partner placements. Cash sits at $66.0M with $40M revolver available after paying off term debt in July; OCF hit $25.5M YTD. Share buybacks trimmed the float. Qui tam suits over Medicare claims linger, stayed through November.
8-K
Q3 beats, buyback launched
Tactile Medical posted Q3 revenue up 17% to $85.8M, net income of $8.2M, and gross margin at 76%, fueled by 71% airway clearance growth. Board authorized $25M share repurchases through November 2027, funded by cash. Raised 2025 guidance to $317-321M revenue, $38-39.5M adjusted EBITDA. Debt-free now.
ELMD
Electromed, Inc.
29.88+0.28
EMED
Electromedical Technologies, In
0.00+0.00
HSDT
Solana Company
3.10+0.06
INSP
Inspire Medical Systems, Inc.
115.51-3.75
NMTC
NeuroOne Medical Technologies C
0.71+0.05
NXL
Nexalin Technology, Inc.
0.81-0.01
SENS
Senseonics Holdings, Inc.
6.62-0.17
TMDX
TransMedics Group, Inc.
125.04+1.89
VERO
Venus Concept Inc.
2.26+0.59
VMD
Viemed Healthcare, Inc.
7.26-0.11